New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
04:55 EDTMRGE, MRGE, KND, KND, IMMU, IMMU, COO, COO, CVS, CVS, ARNA, ARNA, GMED, GMED, ISIS, ISIS, Q, Q, STML, STML, BDSI, BDSI, DEPO, DEPOWells Fargo to hold a conference
2014 Healthcare Conference to be held in Boston on June 17-18.
News For MRGE;BDSI;STML;Q;ISIS;GMED;ARNA;CVS;COO;IMMU;KND;DEPO From The Last 14 Days
Check below for free stories on MRGE;BDSI;STML;Q;ISIS;GMED;ARNA;CVS;COO;IMMU;KND;DEPO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 15, 2014
06:07 EDTCVSCVS Health upgraded to Outperform from Market Perform at Cowen
September 12, 2014
12:20 EDTIMMUImmunomedics management to meet with Jefferies
Subscribe for More Information
September 11, 2014
12:42 EDTARNAOrexigen falls after FDA requires warnings on Contrave label
Subscribe for More Information
12:29 EDTCOOCooper Companies reaffirms Q4, FY14 EPS/ revenue guidance given on Sept. 4
Guidance reaffirmed in presentation slides at 2014 analyst meeting.
12:27 EDTCOOCooper Companies sees FY15 adjusted EPS $8.20-$8.60, consensus $8.40
Subscribe for More Information
10:59 EDTARNAArena competition picks up after Contrave approval, says Piper Jaffray
Subscribe for More Information
08:01 EDTARNAOrexigen Contrave could have stronger launch than peers, says Wells Fargo
After the FDA approved Orexigen's (OREX) Contrave as a treatment option for chronic weight management, Wells Fargo does not believe the label included any significant surprises. The firm thinks multiple factors increase the chances that Contrave's launch will be stronger than two other weight loss drugs that were launched in recent years by VIVUS and Arena Pharmaceuticals (ARNA). The firm keeps an Outperform rating on Orexigen.
07:25 EDTSTMLAegis to hold a conference
Subscribe for More Information
07:19 EDTGMEDGlobus Medical reiterated as top pick at Piper Jaffray
Piper Jaffray reiterates Globus Medical as a top pick and raised its price target for shares to $28 from $26. Piper views the stock's valuation as among the most compelling in its coverage universe. It believes Globus' underlying business is solid and reiterates an Overweight rating on the stock. JMP Securities this morning initiated Globus Medical with an Outperform rating and $25 price target.
06:24 EDTGMEDGlobus Medical initiated with an Outperform at JMP Securities
Subscribe for More Information
September 9, 2014
12:46 EDTARNANovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information
September 8, 2014
11:27 EDTCOOCooper Companies to host analyst meeting
Subscribe for More Information
08:52 EDTBDSIBioDelivery Sciences price target raised to $28 from $20 at Summer Street
Summer Street raised its price target for BioDelivery Sciences shares to $28 saying it left the company's analyst day on Friday incrementally more positive. The firm believes its sales estimates for Bunavail and BEMA Buprenorphine may prove to be conservative and reiterates a Buy rating on the stock.
08:01 EDTCVSCVS Health completes purchase of Navarro Discount Pharmacy
Subscribe for More Information
07:26 EDTQ, CVSMorgan Stanley to hold a conference
Subscribe for More Information
September 5, 2014
14:36 EDTDEPODepomed summary judgement motion granted in Gralise suit against FDA
Depomed announced that Judge Kentaji Brown Jackson of the federal district court for the District of Columbia has granted Depomed's motion for summary judgment in the company's lawsuit against the FDA seeking an order requiring the FDA to grant Gralise Orphan Drug exclusivity for the management of postherpetic neuralgia. The court's ruling requires that the FDA grant Orphan Drug exclusivity for Gralise for the management of PHN.
September 4, 2014
16:21 EDTCOOCooper Companies raises FY14 EPS view to $7.34-$7.44 from $6.80-$7.00
Consensus $6.84. Raises FY14 revenue guidance to $1.73B-$1.74B from $1.69B-$1.73B, consensus $1.75B.
16:19 EDTCOOCooper Companies sees Q4 EPS $2.00-$2.10, consensus $1.82
Sees Q4 revenue $477M-$490M, consensus $494.24M.
16:18 EDTCOOCooper Companies reports Q3 EPS $1.90, consensus $1.90
Subscribe for More Information
15:23 EDTCOONotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Cooper Companies (COO), consensus $1.90; Esterline Technologies (ESL), consensus $1.40; Verint Systems (VRNT), consensus 60c; Finisar (FNSR), consensus 32c; Zumiez (ZUMZ), consensus 23c; SeaChange (SEAC), consensus (18c); Ambarella (AMBA), consensus 28c; Infoblox (BLOX), consensus 1c.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use